Product identity first
“Tirzepatide injection” can describe different prescription products
Tirzepatide is the active ingredient in FDA-approved Mounjaro and Zepbound injections, but the brands have different labeled-use contexts. Mounjaro labeling addresses type 2 diabetes, while Zepbound labeling addresses chronic weight management and certain obstructive sleep apnea care. Peptide12 also lists a clinician-reviewed compounded tirzepatide injection pathway. A compounded preparation is patient-specific and may differ in concentration, container, inactive ingredients, storage, beyond-use date, supplies, and directions. Resolve the exact product before answering a missed-injection question.
- Keep the carton, device or vial, pharmacy label, prescription date, strength or concentration, lot or refill details, and dose record available.
- Confirm whether an injection was truly missed; an uncertain record or possible duplicate injection requires professional review rather than a guess.
- Do not transfer instructions among Mounjaro, Zepbound, compounded tirzepatide, semaglutide, retatrutide, or another product.
Current branded-label rule
Mounjaro and Zepbound use a four-day missed-dose window
The current Eli Lilly manufacturer labels for Mounjaro and Zepbound, both effective April 22, 2026, say to administer one missed dose as soon as possible within four days, or 96 hours, after it was missed. If more than four days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In either case, resume the regular once-weekly schedule. This is a label instruction for one routine missed dose, not permission to calculate a catch-up amount or combine injections.
- Count from the scheduled injection date and time, not from when the reminder was noticed.
- If timing is close to the four-day boundary or cannot be reconstructed, ask the pharmacist or prescriber instead of rounding.
- Do not double the next dose or use extra medicine to compensate for the gap.
Spacing and schedule changes
Keep at least 72 hours between two branded tirzepatide doses
The current Mounjaro and Zepbound labels say the weekly administration day may be changed when necessary as long as at least three days, or 72 hours, separate two doses. This minimum interval is not permission to add an injection, alternate weekdays repeatedly, compress a clinician-directed plan, or take two doses to return to a preferred day. Exact dates and times matter when a missed dose and a schedule change overlap.
- Document a changed weekly day in the medication record, refill reminders, and follow-up plan.
- Do not take two branded tirzepatide doses within three days of each other.
- Seek prompt product-specific help if two injections may have been taken too close together or the amount is uncertain.
Compounded tirzepatide
The patient-specific prescription and pharmacy label control the question
A compounded tirzepatide injection is not FDA-approved Mounjaro, FDA-approved Zepbound, or an FDA-approved generic finished drug product. Although the active ingredient may be tirzepatide, the patient-specific prescription can have different concentration, container, supplies, directions, storage, and beyond-use information. The responsible prescriber and dispensing pharmacist should verify the preparation, last injection, duration of the gap, symptoms, current directions, and refill history before giving catch-up or restart instructions.
- Do not copy a branded pen calendar, online syringe chart, another patient’s instructions, or a social-media restart plan.
- Do not use an unlabeled vial, research-use product, hidden-pharmacy offer, or no-prescription tirzepatide seller to fill a calendar gap.
- Ask whether a refill or pharmacy change altered concentration, presentation, supplies, directions, storage, or beyond-use date.
Long gaps and medication coordination
Several missed weeks need more than the routine four-day answer
The branded four-day instruction does not establish a universal restart plan after multiple missed weeks. Prior strength, tolerability, the reason for the interruption, current gastrointestinal symptoms, hydration, glucose pattern, product or presentation changes, pregnancy, procedures, and other medicines may affect the clinician’s decision. Tirzepatide can increase hypoglycemia risk when combined with insulin or an insulin secretagogue such as a sulfonylurea. A missed injection does not authorize independent changes to another medicine.
- Share glucose or CGM readings when relevant, food and fluid intake, vomiting or diarrhea, urine output, abdominal symptoms, and the complete medication list.
- Do not independently restart, reduce, increase, split, stretch, combine, or convert injections after a prolonged interruption.
- Do not stop, add, reduce, or increase insulin, a sulfonylurea, or another glucose-lowering medicine solely because tirzepatide was late or skipped.
Symptoms and urgent help
Significant symptoms can be more important than the calendar
Contact the care team promptly when the missed injection overlaps with persistent vomiting or diarrhea, low intake, dehydration, severe constipation, significant abdominal pain, illness, pregnancy, a planned procedure, storage damage, or a changed product. Use urgent or emergency care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, fainting, confusion, seizure, severe glucose symptoms, trouble breathing, or facial or throat swelling. For a possible overdose or uncertain extra dose, contact the healthcare provider or Poison Help at 1-800-222-1222; use emergency services for severe symptoms.
- Bring the exact package, pharmacy label, dose record, dates and times, symptom timeline, and medication list when requesting help.
- Do not wait for a routine portal reply when severe allergy, dehydration, abdominal, neurologic, or glucose symptoms are present.
- A legitimate telehealth pathway should identify the exact product and pharmacy before giving timing advice.